Recent studies reveal additional driver genes in ccRCC pathogenesis, highlighting ongoing research into VHL biology and potential new treatments (Belzutifan PT2977, FDA approved in 2021 [25–27], but the VHL role in UM hasn’t been explored yet. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.